{"id":"egt0001442","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"There is limited information available on EGT0001442's mechanism of action, and it is not well understood at this time.","oneSentence":"EGT0001442's mechanism of action is currently unknown.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T02:36:48.085Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT03514641","phase":"PHASE2, PHASE3","title":"An Integrated Assessment of the Safety and Effectiveness of Bexagliflozin for the Management of Essential Hypertension","status":"COMPLETED","sponsor":"Theracos","startDate":"2017-10-18","conditions":"Essential Hypertension","enrollment":673},{"nctId":"NCT03197324","phase":"PHASE1","title":"Bexagliflozin Drug/Drug Interaction Study With Digoxin","status":"COMPLETED","sponsor":"Theracos","startDate":"2017-07-24","conditions":"Type2 Diabetes Mellitus","enrollment":20},{"nctId":"NCT02558296","phase":"PHASE3","title":"Bexagliflozin Efficacy and Safety Trial","status":"COMPLETED","sponsor":"Theracos","startDate":"2015-10","conditions":"Type 2 Diabetes Mellitus","enrollment":1700},{"nctId":"NCT03259789","phase":"PHASE3","title":"Safety and Efficacy of Bexagliflozin Compared to Placebo as Add-on Therapy to Metformin in Type 2 Diabetes Subjects","status":"COMPLETED","sponsor":"Theracos","startDate":"2017-11-28","conditions":"Type2 Diabetes Mellitus","enrollment":351},{"nctId":"NCT03296800","phase":"PHASE1","title":"Study to Evaluate Effects of Probenecid, Rifampin and Verapamil on Bexagliflozin in Healthy Subjects","status":"COMPLETED","sponsor":"Theracos","startDate":"2017-09-27","conditions":"Type 2 Diabetes Mellitus","enrollment":48},{"nctId":"NCT01377844","phase":"PHASE2","title":"Efficacy and Safety of EGT0001442 in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Theracos","startDate":"2011-12","conditions":"Diabetes Mellitus","enrollment":288},{"nctId":"NCT02836873","phase":"PHASE3","title":"Safety and Efficacy of Bexagliflozin in Type 2 Diabetes Mellitus Patients With Moderate Renal Impairment","status":"COMPLETED","sponsor":"Theracos","startDate":"2016-09-23","conditions":"Type 2 Diabetes Mellitus","enrollment":312},{"nctId":"NCT02390050","phase":"PHASE2","title":"A Dose Range Finding Study to Evaluate the Effect of Bexagliflozin Tablets in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Theracos","startDate":"2015-05-12","conditions":"Diabetes Mellitus, Type 2","enrollment":292},{"nctId":"NCT02715258","phase":"PHASE3","title":"Safety and Efficacy of Bexagliflozin as Monotherapy in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Theracos","startDate":"2016-03","conditions":"Type 2 Diabetes Mellitus","enrollment":210},{"nctId":"NCT03115112","phase":"PHASE3","title":"Safety and Efficacy of Bexagliflozin Compared to Sitagliptin as Add-on Therapy to Metformin in Type 2 Diabetes Subjects","status":"COMPLETED","sponsor":"Theracos","startDate":"2017-10-12","conditions":"Type 2 Diabetes Mellitus","enrollment":386},{"nctId":"NCT01029704","phase":"PHASE2","title":"Safety and Efficacy Study of EGT0001442 in Subjects With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Theracos","startDate":"2009-12","conditions":"Diabetes Mellitus Type 2","enrollment":151},{"nctId":"NCT02820298","phase":"PHASE1","title":"Study to Evaluate the Effects of a High-Fat Meal on Bexagliflozin in Healthy Subjects","status":"COMPLETED","sponsor":"Theracos","startDate":"2016-06-20","conditions":"Type 2 Diabetes Mellitus","enrollment":25},{"nctId":"NCT02769481","phase":"PHASE3","title":"Safety and Efficacy of Bexagliflozin Compared to Glimepiride as Add-on Therapy to Metformin in Type 2 Diabetes Subjects","status":"COMPLETED","sponsor":"Theracos","startDate":"2016-08-15","conditions":"Type 2 Diabetes Mellitus","enrollment":426},{"nctId":"NCT03417076","phase":"PHASE1","title":"Absolute Bioavailability Study With Bexagliflozin","status":"WITHDRAWN","sponsor":"Theracos","startDate":"2018-08-01","conditions":"Type 2 Diabetes Mellitus","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Bexagliflozin","Human SGLT2 inhibitor"],"phase":"phase_2","status":"active","brandName":"EGT0001442","genericName":"EGT0001442","companyName":"Theracos","companyId":"theracos","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}